| |
All
|
Anti-TNF alone
|
Anti-TNF + DMARDs
|
DMARDs alone
|
|---|
|
Age (years)
|
21 (15–36)
|
23 (15–29)
|
27 (18–32)
|
28 (22–36)
|
|
Gender (male/female)
|
12/44
|
3/15
|
6/15
|
3/14
|
|
Disease duration
|
2 (0.17–10)
|
0.67 (0.17–3)
|
2 (0.75–6)
|
7.5 (3.5–10)
|
|
HLA-B27-positive
|
91.1 % (51/56)
|
88.9 % (16/18)
|
90.5 % (19/21)
|
94.1 % (16/17)
|
|
Baseline
|
|
SPARCC
|
32.45 ± 18.71
|
27.76 ± 18.38
|
39.53 ± 19.21
|
28.67 ± 15.51
|
|
ASDAS
|
2.84 ± 1.26
|
2.56 ± 1.24
|
3.58 ± 1.05
|
2.21 ± 1.03
|
|
ESRa
|
27.10 ± 32.39
|
27.94 ± 33.24
|
38.49 ± 38.50
|
12.14 ± 8.43
|
|
CRPa
|
17.50 ± 23.07
|
16.29 ± 23.05
|
26.29 ± 28.02
|
7.919 ± 5.60
|
-
aNot normally distributed, compared by paired rank test
-
ASDAS Ankylosing Spondylitis Disease Activity Indices, CRP C-reactive protein, DMARD disease-modifying anti-rheumatic drug, ESR erythrocyte sedimentation rate, SPARCC Spondyloarthritis Research Consortium Canada, TNF tumor necrosis factor
